The implementation of diagnostics using ctDNA has been leveraged as a companion diagnostic test, e.g., for detecting EGFR inhibitor sensitive mutations for the use of erlotinib in non-small cell lung cancer [15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.